Impact of metabolic syndrome in patients with acute coronary syndrome

Advances in Cardiology

Volumn 45, Issue , 2008, Pages 114-126

  Feinberg, M ^a   Schwartz, R ^a,b   Behar, S ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE CORONARY SYNDROME; AGED; CLASSIFICATION; DIABETIC ANGIOPATHY; FEMALE; HUMAN; HYPERGLYCEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; REVIEW;

ACUTE CORONARY SYNDROME; AGED; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 43749115800     PISSN: 00652326     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000115191     Document Type: Review

References (29)

1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto JT, Salonen JT: The metabolic syndrome an total and cardiovascular disease mortality in middle aged men. JAMA 2002;288:2709-2016.
2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
3. Levantesi, Macchia A, Marfisi R, Franzosi MG, Maggioni AP, Nicolosi GL, Schweiger C, Tavazzi L, Tognoni G, Valagussa F, Marchioli R, on behalf of the GISSI-Prevenzione Investigators: Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 2005;46:277-283.
4. Zeller M, Steg PG, Ravisy J, Laurent Y, Janin-Manificat L, L'Huillier I, Beer JC, Oudot A, Rioufol G, Makki H, Farnier M, Rochette L, Vergès B, Cottin Y, for the Observatoire des Infarctus de Côted'Or Survey Working Group: Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med 2005;165:1192-1198.
5. Schwartz GG, Szarek M, Olsson AG, Sasiela WJ: Relation of characteristics of metabolic syndrome to short term prognosis and effects of statin therapy after acute coronary syndrome. Diabetes Care 2005;28:2508-2013.
6. Feinberg MS, Schwartz R, Tanne D, Fisman EZ, Hod H, Zahger D, Schwammethal E, Eldar M, Behar S, Tenenbaum A: Impact of the metabolic syndrome on the clinical outcomes of non-clinically diagnosed diabetic patients with acute coronary syndrome. Am J Cardiol 2007;99:667-672.
7. Nakatani D, Sakata Y, Hiroshi Sato H, Mizuno H, Masahiko Shimizu M, Suna S, Ito H, Koretsune Y, Hirayama A, Hori M, on behalf of the Osaka Acute Coronary Insufficiency Study (OACIS) Group: Clinical impact of metabolic syndrome and its additive effect with smoking on subsequent cardiac events after acute myocardial infarction. Am J Cardiol 2007;99:885-889.
8. Clavijo LC, Pinto TL, Kuchulakanti PK, Torguson R, Chu WW, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R: Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications. Cardiovasc Revascular Med 2006;7:7-11.
9. Stone PH, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, Turi ZG, Strauss HW, Willerson JT, Robertson T, et al: The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 1989;14:49-57.
10. Herlitz J, Malmberg K, Karlson BW, Rydén L, Hjalmarson A: Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction. Acta Med Scand 1988;224:31-38.
11. Woods KL, Samanta A, Burden AC: Diabetes mellitus as a risk factor for acute myocardial infarction in Asians and Europeans. Br Heart J 1989;62:118-122.
12. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, American Heart Association, National Heart, Lung, and Blood Institute: Definition of MS: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-438.
13. American Diabetes Association Consensus Statement: Postprandial blood glucose. Diabetes Care 2001:24;775-778.
14. Jonas M, Grossman E, Boyko V, Behar S, Hod H, Reicher-Reiss H: Relation of early and one-year outcome after acute myocardial infarction to systemic arterial blood pressure on admission. Am J Cardiol 1999;84:162-165.
15. Henkin Y, Crystal E, Goldberg Y, Friger M, Lorber J, Zuili I, Shany S: Usefulness of lipoprotein changes during acute coronary syndromes for predicting post-discharge lipoprotein levels. Am J Cardiol 2002;89:7-11.
16. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S: Bezafibrate for the secondary prevention of myocardial infarction in patients with MS. Arch Intern Med 2005;165:1154-1160.
17. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M: Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 2005;26:1255-1261.
18. Stranders I, Diamant M, van Gelder RE, Spruijt HJ, Twisk JWR, Heine RJ, Visser FC: Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med 2004;164:982-988.
19. Grundy SM: Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006;47:1093-1100.
20. Tansey MJ, Opie LH: Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction. Lancet 1983;ii:419-422.
21. Oliver MF, Opie LH: Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994;343:155-158.
22. Tansey MJ, Opie LH: Plasma glucose on admission to hospital as a metabolic index of the severity of acute myocardial infarction. Can J Cardiol 1986;2:326-331.
23. Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C: Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990;322:1769-1774.
24. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS: Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med 1993;10:27-32.
25. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, Creager MA: Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97:1695-1701.
26. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Rydén L, Malmberg K: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-2144.
27. Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, Standl E, Soler-Soler J, Ohrvik J, Euro Heart Survey Investigators: The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: The Euro Heart Survey on Diabetes and the Heart. Eur Heart J 2004;25:1880-1890.
28. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Rydén L: Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004;25:1990-1997.
29. Salmenniemi U, Ruotsalainen E, Pihlajamaki J, Vauhkonen I, Kainulainen S, Punnonen K, Vanninen E, Laakso M: Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 2004;110:3842-3848.